All In Biotech

Drug Trial Radar · NCT06058299

Phase 2 Trial Assessing TBAJ876 or Bedaquiline, With Pretomanid and Linezolid in Adults With Drug-sensitive Pulmonary Tuberculosis

A Phase 2, Partially-blinded, Randomised Trial Assessing the Safety and Efficacy of TBAJ-876 or Bedaquiline, in Combination With Pretomanid and Linezolid in Adult Participants With Newly Diagnosed, Drug-sensitive, Smear-positive Pulmonary Tuberculosis

Last checked: Nov 19, 2026Latest source record: Jun 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingRandomized with 309 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

309

Actual

Start

Oct 31, 2023

Primary completion

Dec 27, 2024

Study completion Feb 2027

Sponsor

Lead sponsor
Global Alliance for TB Drug DevelopmentAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Sep 28, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to evaluate 3 dose levels of TBAJ876 for 8 weeks in combination with pretomanid and linezolid, compared to 8 weeks of Isoniazid, rifampicin, pyrazinamide and ethambutol (2HRZE), in adult participants with newly diagnosed, smear-positive, pulmonary drug sensitive tuberculosis (DS-TB). The main questions the trial aims to answer are: * What is the optimal dose of TBAJ876 to continue further in development. * What is the bactericidal activity of bedaquiline with pretomanid and linezolid (B-Pa-L) compared to 2HRZE and TBAJ876-Pa-L over 8 weeks * What is the efficacy and safety of the 26-week B-Pa-L regimen compared with the SOC (2HRZE/4HR) in participants with DS-TB. Participants will be seen regularly during treatment (up to 26 weeks) and follow-up (52 weeks post treatment) for safety and efficacy assessments, including but not limited to: * Safety labs, ECGs, vital signs, physical exams, PK sampling, neuropathy assessments and adverse event monitoring * Sputum collection

Conditions

  • Pulmonary TB
  • Pulmonary Tuberculosis
  • Drug Sensitive Tuberculosis

Interventions

  • sorfequilineDrug

    tablet

  • PretomanidDrug

    tablet

  • LinezolidDrug

    tablet

  • BedaquilineDrug

    tablet

  • HRZEDrug

    fixed doe combination tablets

  • HRDrug

    fixed dose combination tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of Participants With Stable Sputum Conversion by 8 Weeks,Time frame: Through 8 weeks of treatment

Locations

22 sites in 5 countries. Site status is shown where the registry gives one.

  • National Center for Tuberculosis and Lung Diseases

    Tbilisi, Georgia

  • Care Clinical Trial Group Inc.

    Dasmariñas, Philippines

  • Tropical Disease Foundation

    Makati City, Philippines

  • Lung Center of the Philippines

    Quezon City, Philippines

  • Madibeng Centre for Research

    Brits, South Africa

  • TASK Brooklyn

    Cape Town, South Africa

  • University of Cape Town Lung Institute (UCTLI)

    Cape Town, South Africa

  • Desmond Tutu Health Foundation

    Cape Town, South Africa

  • Enhancing Care Foundation

    Durban, South Africa

  • Synergy Biomed Research Institute (SBRI)

    East London, South Africa

  • TASK Eden

    George, South Africa

  • TB and HIV Investigative Network (THINK)

    Hillcrest, South Africa

  • WITS, Clinical HIV Research Unit (CHRU) Themba Lethu Clinic, Helen Joseph Hospital

    Johannesburg, South Africa

  • Perinatal HIV Research Unit (PHRU)

    Klerksdorp, South Africa

  • Isango Lethemba TB Research Unit

    Port Elizabeth, South Africa

  • The Aurum Institute

    Rustenburg, South Africa

  • Setshaba Research Centre

    Soshanguve, Gauteng, South Africa

  • NIMR-MBEYA Medical Research Center

    Mbeya, Tanzania

  • Kilimanjaro Christian Medical Centre

    Moshi, Tanzania

  • National Institute for Medical Research (NIMR)

    Mwanza, Tanzania

  • Case Western Reserve University- Research collaboration Uganda

    Kampala, Uganda

  • Joint Clinical Research Centre (JCRC)

    Kampala, Uganda

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.